微小RNA作为肺癌的工具和治疗手段
MicroRNA as tools and therapeutics in lung cancer.
作者信息
Barger Jennifer F, Nana-Sinkam S Patrick
机构信息
The Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA; Dept. Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University, Columbus, OH 43210, USA.
The Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA; Dept. Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University, Columbus, OH 43210, USA; The Ohio State University James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
出版信息
Respir Med. 2015 Jul;109(7):803-12. doi: 10.1016/j.rmed.2015.02.006. Epub 2015 Feb 19.
Lung cancer is the number one cause of cancer related deaths. The lack of specific and accurate tools for early diagnosis and minimal targeted therapeutics both contribute to poor outcomes. The recent discovery of microRNAs (miRNAs) revealed a novel mechanism for post-transcriptional regulation in cancer and has created new opportunities for the development of diagnostics, prognostics and targeted therapeutics. In lung cancer, miRNA expression profiles distinguish histological subtypes, predict chemotherapeutic response and are associated with prognosis, metastasis and survival. Furthermore, miRNAs circulate in body fluids and hence may serve as important biomarkers for early diagnosis or stratify patients for personalized therapeutic strategies. Here, we provide an overview of the miRNAs implicated in lung cancer, with an emphasis on their clinical utility.
肺癌是癌症相关死亡的首要原因。缺乏用于早期诊断的特异性和准确工具以及极少的靶向治疗方法，这两者都导致了不良后果。微小RNA（miRNA）的最新发现揭示了癌症中一种新的转录后调控机制，并为诊断、预后评估和靶向治疗的发展创造了新机会。在肺癌中，miRNA表达谱可区分组织学亚型、预测化疗反应，并与预后、转移和生存相关。此外，miRNA在体液中循环，因此可能作为早期诊断的重要生物标志物，或为个性化治疗策略对患者进行分层。在此，我们概述了与肺癌相关的miRNA，重点介绍它们的临床应用。
Zotero 插件